Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 Current Ratio is 1.88 as of Dec. 2025, which is 31% below its 10-year median of 2.74. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Bio View ranks worse than 64.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bio View's current ratio for the quarter that ended in Dec. 2025 was 1.88.
Bio View has a current ratio of 1.88. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bio View's Current Ratio or its related term are showing as below:
XTAE:BIOV'
s Current Ratio Range Over the Past 10 Years
Min: 1.88 Med: 2.74 Max: 3.52
Current: 1.88
During the past 13 years, Bio View's highest Current Ratio was 3.52. The lowest was 1.88. And the median was 2.74.
XTAE:BIOV's Current Ratio is ranked worse than 64.04% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs XTAE:BIOV: 1.88
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bio View Current Ratio Related Terms
Bio View Current Ratio Historical Data
* Premium members only.
The historical data trend for Bio View's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Bio View's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bio View's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a Current Ratio of 1.88 as of Dec. 2025. This is 31% below median its historical median of 2.74. Over the past decade, Bio View's Current Ratio has ranged from 1.88 to 3.52. According to the industry distribution chart, Bio View ranks #545 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 64%.
Is Bio View's Current Ratio too high?
Bio View's current Current Ratio of 1.88 is 31% below median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 3.52. The Medical Devices & Instruments industry median Current Ratio is 2.45. Bio View's value of 1.88 is 23.3% below this industry median. Based on the distribution chart, Bio View ranks #545 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #545 out of 851 companies for Current Ratio. This places Bio View in the lower half of its industry. The industry median Current Ratio is 2.45. Bio View's value of 1.88 is 23.3% below this benchmark. Historically, Bio View's own Current Ratio has ranged from 1.88 to 3.52 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 2.45, Bio View has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.45, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio View's current Current Ratio of 1.88 is 23.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current Current Ratio is 1.88, which is 31% below median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current Current Ratio is 1.88, which is 31% below median its 10-year median of 2.74 and 23.3% below the Medical Devices & Instruments industry median of 2.45. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current Current Ratio is 1.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
Current Ratio: 1.88 (31% below median its 10-year median of 2.74)
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
Industry Position: 23.3% below the Medical Devices & Instruments median (#545 of 851)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
